Медицинская библиотека · Cancer immunology, immunotherapy : CII · 2023

Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.

Fiala Ondřej, Buti Sebastiano, Takeshita Hideki, Okada Yohei, Massari Francesco, Palacios Georgia Anguera, Dionese Michele, Scagliarini Sarah, Büttner Thomas, Fornarini Giuseppe, Myint Zin W, Galli Luca, Souza Vinicius Carrera, Pichler Renate, De Giorgi Ugo, Quiroga María Natalia Gandur, Gilbert Danielle, Popovic Lazar, Grande Enrique, Mammone Giulia, Berardi Rossana, Crabb Simon J, Molina-Cerrillo Javier, Freitas Marcelo, Luz Murilo, Iacovelli Roberto, Calabrò Fabio, Tural Deniz, Atzori Francesco, Küronya Zsófia, Chiari Rita, Campos Saul, Caffo Orazio, Fay André P, Kucharz Jakub, Zucali Paolo Andrea, Rinck José Augusto, Zeppellini Annalisa, Bastos Diogo Assed, Aurilio Gaetano, Mota Augusto, Trindade Karine, Ortega Cinzia, Sade Juan Pablo, Rizzo Mimma, Vau Nuno, Giannatempo Patrizia, Barillas Allan, Monteiro Fernando Sabino Marques, Dauster Breno, Cattrini Carlo, Nogueira Lucas, de Carvalho Fernandes Roni, Seront Emmanuel, Aceituno Luís Garcia, Grillone Francesco, Cutuli Hernan Javier, Fernandez Mauricio, Bassanelli Maria, Roviello Giandomenico, Abahssain Halima, Procopio Giuseppe, Milella Michele, Kopecky Jindrich, Martignetti Angelo, Messina Carlo, Caitano Manuel, Inman Eva, Kanesvaran Ravindran, Herchenhorn Daniel, Santini Daniele, Manneh Ray, Bisonni Renato, Zakopoulou Roubini, Mosca Alessandra, Morelli Franco, Maluf Fernando, Soares Andrey, Nunes Fernando, Pinto Alvaro, Zgura Anca, Incorvaia Lorena, Ansari Jawaher, Zabalza Ignacio Ortego, Landmesser Johannes, Rizzo Alessandro, Mollica Veronica, Sorgentoni Giulia, Battelli Nicola, Porta Camillo, Bellmunt Joaquim, Santoni Matteo

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Concomitant medications may potentially affect the outcome of cancer patients. In this sub-analysis of the ARON-2 real-world study (NCT05290038), we aimed to assess the impact of concomitant use of proton pump inhibitors (PPI), statins, or metformin on outcome of patients with metastatic urothelial cancer (mUC) receiving second-line pembrolizumab.

METHODS

We collected data from the hospital medical records of patients with mUC treated with pembrolizumab as second-line therapy at 87 institutions from 22 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate. We carried out a survival analysis by a Cox regression model.

RESULTS

A total of 802 patients were eligible for this retrospective study; the median follow-up time was 15.3 months. PPI users compared to non-users showed inferior PFS (4.5 vs. 7.2 months, p = 0.002) and OS (8.7 vs. 14.1 months, p < 0.001). Concomitant PPI use remained a significant predictor of PFS and OS after multivariate Cox analysis. The use of statins or metformin was not associated with response or survival.

CONCLUSIONS

Our study results suggest a significant prognostic impact of concomitant PPI use in mUC patients receiving pembrolizumab in the real-world context. The mechanism of this interaction warrants further elucidation.

Для цитирования: Fiala Ondřej, Buti Sebastiano, Takeshita Hideki, Okada Yohei, Massari Francesco, Palacios Georgia Anguera, Dionese Michele, Scagliarini Sarah, Büttner Thomas, Fornarini Giuseppe, Myint Zin W, Galli Luca, Souza Vinicius Carrera, Pichler Renate, De Giorgi Ugo, Quiroga María Natalia Gandur, Gilbert Danielle, Popovic Lazar, Grande Enrique, Mammone Giulia, Berardi Rossana, Crabb Simon J, Molina-Cerrillo Javier, Freitas Marcelo, Luz Murilo, Iacovelli Roberto, Calabrò Fabio, Tural Deniz, Atzori Francesco, Küronya Zsófia, Chiari Rita, Campos Saul, Caffo Orazio, Fay André P, Kucharz Jakub, Zucali Paolo Andrea, Rinck José Augusto, Zeppellini Annalisa, Bastos Diogo Assed, Aurilio Gaetano, Mota Augusto, Trindade Karine, Ortega Cinzia, Sade Juan Pablo, Rizzo Mimma, Vau Nuno, Giannatempo Patrizia, Barillas Allan, Monteiro Fernando Sabino Marques, Dauster Breno, Cattrini Carlo, Nogueira Lucas, de Carvalho Fernandes Roni, Seront Emmanuel, Aceituno Luís Garcia, Grillone Francesco, Cutuli Hernan Javier, Fernandez Mauricio, Bassanelli Maria, Roviello Giandomenico, Abahssain Halima, Procopio Giuseppe, Milella Michele, Kopecky Jindrich, Martignetti Angelo, Messina Carlo, Caitano Manuel, Inman Eva, Kanesvaran Ravindran, Herchenhorn Daniel, Santini Daniele, Manneh Ray, Bisonni Renato, Zakopoulou Roubini, Mosca Alessandra, Morelli Franco, Maluf Fernando, Soares Andrey, Nunes Fernando, Pinto Alvaro, Zgura Anca, Incorvaia Lorena, Ansari Jawaher, Zabalza Ignacio Ortego, Landmesser Johannes, Rizzo Alessandro, Mollica Veronica, Sorgentoni Giulia, Battelli Nicola, Porta Camillo, Bellmunt Joaquim, Santoni Matteo. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.. Cancer immunology, immunotherapy : CII. 2023. DOI: 10.1007/s00262-023-03518-z.

Предметные рубрики MeSH

Humans Proton Pump Inhibitors Hydroxymethylglutaryl-CoA Reductase Inhibitors Metformin Carcinoma, Transitional Cell Retrospective Studies Urinary Bladder Neoplasms Antibodies, Monoclonal, Humanized

Подготовка и перевод публикации

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.